N@N

Andrew Fein Maintained (VRTX) at Strong Buy with Increased Target to $300 on, Aug 5th, 2022

Andrew Fein of HC Wainwright & Co., Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $275 to $300 on, Aug 5th, 2022.

Andrew has made no other calls on VRTX in the last 4 months.

There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 4 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $256 on, Tuesday, July 26th, 2022
• David Risinger of "SVB Leerink" Initiated at Hold and Held Target at $265 on, Monday, May 23rd, 2022
• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
• Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022

These are the ratings of the 7 analyists that currently disagree with Andrew

---

• Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $365 on, Wednesday, July 13th, 2022
• Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $280 on, Monday, June 13th, 2022
• Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $310 on, Monday, June 13th, 2022
• Jason McCarthy of "Maxim Group" Upgraded from Hold to Strong Buy and Held Target at $325 on, Wednesday, June 1st, 2022
• Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 24th, 2022
• Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
• Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022

Contributing Sources

---